Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alfredo Belcastro
Institution:
University of Rome Tor Vergata
Observed institutions:
University of Rome Tor Vergata,
Policlinico Tor Vergata
ORCID:
0009-0004-2140-7034
Observed ORCID:
0009-0004-2140-7034
OpenAlex ID:
A5008137648
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks
2023
·
Marco Galluzzo
, Lorenzo Marcelli
, et al.
·
Expert Opinion on Biological Therapy
·
27
Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience
2024
·
Lorenzo Marcelli
, Alfredo Belcastro
, et al.
·
Journal of Clinical Medicine
·
17
Predictive factors for eczematous eruptions and candidiasis during anti-interleukin-17 treatment in patients with psoriasis: a multicentre real-life experience in Lazio region, Italy
2025
·
Giacomo Caldarola
, Eleonora De Luca
, et al.
·
Clinical and Experimental Dermatology
·
13
PDF
Eczematous liraglutide eruption managed by dupilumab: A case report
2024
·
Claudia Paganini
, Alfredo Belcastro
, et al.
·
JAAD Case Reports
·
7
Rosacea-like eruptions associated with upadacitinib in atopic dermatitis: two case reports and management strategies
2025
·
Claudia Paganini
, Edoardo Mortato
, et al.
·
Dermatology Reports
·
4
Could Disease Duration Influence Response to Dupilumab in Patients With Atopic Dermatitis? A Retrospective Real‐Life Study
2025
·
Edoardo Mortato
, Marina Talamonti
, et al.
·
International Journal of Dermatology
·
2
Effects of Guselkumab on the FIB ‐4 Index in Psoriasis Patients ( EGIPT ): A Three‐Year Study
2025
·
Edoardo Mortato
, Lorenzo Marcelli
, et al.
·
The Journal of Dermatology
·
2
PDF
Comment on ‘A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council’: a case of rhabdomyolysis induced by upadacitinib
2024
·
Edoardo Mortato
, Marina Talamonti
, et al.
·
British Journal of Dermatology
·
1
Real-world effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis: a retrospective observational study with focus on head and neck involvement
2026
·
Edoardo Mortato
, Claudia Paganini
, et al.
·
Dermatology Reports
PDF
Predictive Factors of Super‐Responder Status to Dupilumab in Adult Atopic Dermatitis: A Real‐World Monocentric Study
2026
·
Edoardo Mortato
, Marina Talamonti
, et al.
·
International Journal of Dermatology
PDF
Show more works
View as search
Works count:
10
Citation count:
73
H-index:
4
I10-index:
3
Year
Topic
Type